Senator Tony Hwang Applauds CT’s Pfizer on FDA EUA Approval for New COVID-19 Drug

December 23, 2021

HARTFORD – Senator Tony Hwang (R-28), as co-chair of the Bioscience Caucus and a supporter of bioscience and pharmaceutical sciences, applauds the just-announced FDA Emergency Use Authorization of Pfizer’s CT based research and development laboratory in discovering an oral antiviral treatment, called PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). This breakthrough medication is designed to mitigate the dangerous symptoms of COVID-19 in pill-form to save lives and mitigate devastating and potentially deadly results.


“Once again, Connecticut’s own Pfizer is on the forefront of innovation and medical breakthroughs in the effort to eradicate COVID-19. PAXLOVID™ tablets were developed in the Groton, CT research and development laboratory and underwent their first clinical trials in New Haven. This landmark bioscience achievement is an uplifting indicator that CT’s bioscience industry and scientists are constantly thinking through new solutions to enable us to begin to cope with and ultimately ‘beat’ this pandemic instead of placing our lives on hold while hoping for this to pass,” said Sen. Hwang. “Pfizer was first to develop the COVID-19 vaccine, and now they are first to take the next step to help reduce the dangerous and devastating pandemic health risks. I am incredibly grateful and optimistic for us to have another available tool to manage COVID-19 infections and variants.”


Albert Bourla, Chairman and Chief Executive Officer, Pfizer offered in a written statement upon FDA EUA approval, “Today’s authorization of PAXLOVID represents another tremendous example of how science will help us ultimately defeat this pandemic, which, even two years in, continues to disrupt and devastate lives  across the world. This breakthrough therapy, which has been shown to significantly reduce hospitalizations and deaths and can be taken at home, will change the way we treat COVID-19, and  hopefully help reduce some of the significant pressures facing our healthcare and hospital systems. Pfizer stands ready to begin delivery  in the U.S. immediately to help get PAXLOVID into the hands of appropriate patients as quickly as possible.”